Targeted Approaches in Myelodysplastic Syndromes and Myelofibrosis

Experts on myelofibrosis and myelodysplastic syndromes discuss recent data updates, including those presented at the 2022 American Society of Hematology (ASH) Annual Meeting, and provide their outlook on the future of treatment for each.

EP. 1: Classification Systems for MDS

January 18th 2023

Distinguished experts in hematology discuss the WHO and ICC classification systems for myelodysplastic syndromes (MDS), including recent WHO updates.

EP. 2: IPSS-M and IPSS-R Tools for Risk Stratification of MDS

January 18th 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, compare the available IPSS-M and IPSS-R tools for stratifying risk and assessing prognosis in MDS.

EP. 3: IMerge: Updated Safety and Efficacy Data on Imetelstat for Lower-Risk MDS

January 25th 2023

Hematology experts highlight recent data updates from the IMerge trial on the telomerase inhibitor imetelstat, which is being studied for lower-risk MDS.

EP. 4: Trial Updates on Low-Dose Lenalidomide and Luspatercept

January 25th 2023

An overview of updates from the Sintra-REV trial of low-dose lenalidomide, and data from COMMANDS, MEDALIST, and real-world studies on luspatercept.

EP. 5: Oral Hypomethylating Agents in MDS: Data Updates

February 1st 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, discuss trial updates on oral hypomethylating agents, including data on dosing, for treatment of lower-risk MDS.

EP. 6: Data on Emerging Therapies for Treatment of Higher-Risk MDS

February 1st 2023

Experts in hematology take a detailed look at new data on investigational therapies for higher-risk MDS, including the STIMULUS-MDS1 trial on sabatolimab.

EP. 7: Myelofibrosis: Treatment Landscape and Recent Data Updates on JAK2 Inhibitors

February 8th 2023

A comprehensive review of the treatment landscape for myelofibrosis (MF) and recent ASCO and ASH data updates on JAK2 inhibitors.

EP. 8: Remaining Unmet Needs and Additional Ongoing Trials in MF

February 8th 2023

Dr Komrokji summarizes the remaining unmet needs in the treatment of MF, including suboptimal responses to JAK2 inhibitors, and comments on data from ongoing trials that may address these needs.

EP. 9: Closing Remarks on Advances and Future Directions in MF and MDS

February 15th 2023

Amer Zeidan, MBBS, and Rami Komrokji, MD, offer closing remarks on recent advances in MF and MDS, and look towards the future of treatment.